Exploring cellular markers of metabolic syndrome in peripheral blood mononuclear cells across the neuropsychiatric spectrum

Autor: Paula Suárez-Pinilla, Jordan M. Ramsey, Bonnie Auyeug, Volker Arolt, Jantine A. C. Broek, Tillmann Ruland, Marina Rubey, Olya Mikova, Javier Vázquez-Bourgon, Sergi Papiol, Frieder Haenisch, Sabine Bahn, Emiliano Gonzalez-Vioque, Santiago G. Lago, Geertje F. van Rees, Nikolett Kabacs, Jakub Tomasik, Benedicto Crespo-Facorro, Simon Baron-Cohen
Přispěvatelé: Universidad de Cantabria, Stanley Medical Research Institute, Engineering and Physical Sciences Research Council (UK), Government of the Netherlands, Netherlands Genomics Initiative, European Commission, Ministerio de Economía y Competitividad (España), Instituto de Salud Carlos III
Rok vydání: 2021
Předmět:
Zdroj: Brain, Behavior, and Immunity. Volume 91, January 2021, Pages 673-682
UCrea Repositorio Abierto de la Universidad de Cantabria
Universidad de Cantabria (UC)
Digital.CSIC. Repositorio Institucional del CSIC
instname
ISSN: 0889-1591
DOI: 10.1016/j.bbi.2020.07.043
Popis: Recent evidence suggests that comorbidities between neuropsychiatric conditions and metabolic syndrome may precede and even exacerbate long-term side-effects of psychiatric medication, such as a higher risk of type 2 diabetes and cardiovascular disease, which result in increased mortality. In the present study we compare the expression of key metabolic proteins, including the insulin receptor (CD220), glucose transporter 1 (GLUT1) and fatty acid translocase (CD36), on peripheral blood mononuclear cell subtypes from patients across the neuropsychiatric spectrum, including schizophrenia, bipolar disorder, major depression and autism spectrum conditions (n = 25/condition), relative to typical controls (n = 100). This revealed alterations in the expression of these proteins that were specific to schizophrenia. Further characterization of metabolic alterations in an extended cohort of first-onset antipsychotic drug-naïve schizophrenia patients (n = 58) and controls (n = 63) revealed that the relationship between insulin receptor expression in monocytes and physiological insulin sensitivity was disrupted in schizophrenia and that altered expression of the insulin receptor was associated with whole genome polygenic risk scores for schizophrenia. Finally, longitudinal follow-up of the schizophrenia patients over the course of antipsychotic drug treatment revealed that peripheral metabolic markers predicted changes in psychopathology and the principal side effect of weight gain at clinically relevant time points. These findings suggest that peripheral blood cells can provide an accessible surrogate model for metabolic alterations in schizophrenia and have the potential to stratify subgroups of patients with different clinical outcomes or a greater risk of developing metabolic complications following antipsychotic therapy.
This work was supported by grants from the Stanley Medical Research Institute (SMRI); the Engineering and Physical Sciences Research Council UK (EPSRC); the Dutch Government-funded Virgo consortium (ref. FES0908); the Netherlands Genomics Initiative (ref. 050-060-452); the European Union FP7 funding scheme: Marie Curie Actions Industry Academia Partnerships and Pathways (ref. 286334, PSYCH-AID project); SAF2016-76046-R and SAF2013-46292-R (MINECO) and PI16/00156 (ISCIII and FEDER).
Databáze: OpenAIRE
Externí odkaz: